Vertex Pharmaceuticals Inc. (VRTX) reported positive Phase 2b results for Inaxaplin in additional groups of patients with APOL1-mediated kidney disease (AMKD), while also announcing completion of enrolment in its ongoing Phase 2/3 AMPLITUDE trial.
Inaxaplin Shows Kidney Benefit In Additional Patient Groups As Vertex Completes Key Trial Enrollment
